Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
Phase II study results showed comparable viral suppression rates at 96 weeks for a two-drug regimen of long-acting cabotegravir and rilpivirine and a three-drug regimen in patients with HIV
LATTE-2 study results published in The Lancet and presented at International AIDS Society Meeting
-
GSK submits US regulatory filing of Arnuity Ellipta in children with asthma
The sNDA is seeking approval for a dose of 50mcg once-daily, delivered using the Ellipta inhaler in this group of patients.
-
GSK announces Board and Committee changes
GSK - Dr Laurie Glimcher has been appointed to Board of the Company, Non-Executive Director and a Scientific and Medical Expert.
-
GSK submits EU filing for extended use of Relvar Ellipta in patients with controlled asthma on an ICS/LABA combination
GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced a submission to the European Medicines Agency (EMA).
-
GSK receives FDA approval for a new self-injectable formulation of Benlysta (belimumab) for systemic lupus erythematosus
GSK announced today that the US Food and Drug Administration (FDA) has approved a new subcutaneous formulation of Benlysta
-
ViiV Healthcare shares data from its innovative portfolio with HIV community at IAS 2017
ViiV Healthcare shares data from its innovative portfolio with HIV community at IAS 2017
-
GSK updates on UK manufacturing network
GSK today set out several announcements made by the company to improve the efficiency and competitiveness of its manufacturing network.
-
GSK announces US regulatory submission for mepolizumab in Eosinophilic Granulomatosis with Polyangiitis (EGPA)
GSK plc announced the submission of a supplemental Biologics License Application (sBLA) to the United States Food and Drug Administration
-
GSK starts phase III study with mepolizumab in patients with nasal polyps
GlaxoSmithKline plc (LSE/NYSE: GSK) today announced the start of a phase III study with mepolizumab, an interleukin 5 (IL-5) antagonist
-
GSK receives CHMP positive opinion for Synflorix pneumococcal vaccine four-dose vial
New presentation designed to significantly reduce storage requirements in developing countries.
-
GSK presents positive results from Phase III revaccination study of its candidate shingles vaccine Shingrix at CDC’s Advisory Meeting
Study conducted in individuals who had previously received current standard of care
-
GSK announces results from 10-year continuation study showing sustained disease control with Benlysta (belimumab) in SLE
Benlysta is a biologic medicine specifically developed and approved for SLE
-
GSK and MMV announce positive headline phase III results showing single-dose tafenoquine reduces risk of relapse in patients with Plasmodium vivax malaria
GSK and Medicines for Malaria Venture (MMV) today announced positive results from two phase III studies of tafenoquine
-
Four innovations to tackle under-five deaths win US$1 million Healthcare Innovation Award from GSK and Save the Children
Organisations in Pakistan, Colombia, India and Nigeria recognised for innovations helping the hardest-to-reach children HIA (award).
-
ViiV Healthcare
ViiV Healthcare submits regulatory applications for the first HIV maintenance regimen comprising only two medicines
-
ViiV Healthcare submits regulatory applications for the first HIV maintenance regimen comprising only two medicines
ViiV Healthcare submits regulatory applications for the first HIV maintenance regimen comprising only two medicines
-
GSK presents data at ATS on treatment effect of Nucala (mepolizumab) in severe asthma according to blood eosinophil level
GlaxoSmithKline plc (LSE/NYSE:GSK) today presented data from a post-hoc analysis of the phase IIIb MUSCA study
-
GSK announces NEJM publication of positive phase III study investigating mepolizumab in patients with Eosinophilic Granulomatosis with Polyangiitis (EGPA)
GSK announces NEJM publication of phase III study investigating mepolizumab in patients with EGPA
-
GSK announces headline phase III results of mepolizumab in patients with severe chronic obstructive pulmonary disease
GSK plc (LSE/NYSE:GSK) announced preliminary results of two pivotal phase III studies evaluating the efficacy and safety of mepolizumab
-
Relvar Ellipta significantly improved asthma control in Salford Lung Study patients compared with their usual care
Endpoint: patients initiated with Relvar Ellipta had twice the odds of achieving improvement in asthma control than patients in usual care.
